AIMS/ OBJECTIVE: To describe the effectiveness of continuous subcutaneous insulin infusion (CSII) in patients with symptomatic diabetic gastroparesis and unstable glycaemic control. METHODS: Data from 26 patients with symptomatic diabetic gastroparesis and unstable glycaemic control using multiple-dose insulin (MDI) regimens, and subsequently managed with CSII, were analysed. RESULTS: Following initiation of CSII, the median length of inpatient bed days associated with hospital admissions related to gastroparesis and glycaemic instability was reduced from 8.5 (range 0-144) days patient( -1) year( -1) prior to CSII to 0 (range 0-15) days patient( -1) year( -1). The median HbA(1c) reduction with CSII was 1.8% (22 mmol/mol; p < 0.05). The median capillary blood glucose (CBG) with CSII was significantly lower than with MDI: 7.7 mmol/l (range 3.8-15.4 mmol/l) vs 9.8 mmol/l (range 2.3-27 mmol/l), respectively, p < 0.001. Glycaemic variability with CSII was significantly reduced compared with MDI: CBG CV 0.37 vs CV 0.53, respectively, p < 0.001. CONCLUSIONS/ INTERPRETATION: CSII therapy in patients with diabetic gastroparesis results in significant improvement in glycaemic control and reductions in glycaemic variability and number of hospital inpatient bed days.
AIMS/ OBJECTIVE: To describe the effectiveness of continuous subcutaneous insulin infusion (CSII) in patients with symptomatic diabetic gastroparesis and unstable glycaemic control. METHODS: Data from 26 patients with symptomatic diabetic gastroparesis and unstable glycaemic control using multiple-dose insulin (MDI) regimens, and subsequently managed with CSII, were analysed. RESULTS: Following initiation of CSII, the median length of inpatient bed days associated with hospital admissions related to gastroparesis and glycaemic instability was reduced from 8.5 (range 0-144) days patient( -1) year( -1) prior to CSII to 0 (range 0-15) days patient( -1) year( -1). The median HbA(1c) reduction with CSII was 1.8% (22 mmol/mol; p < 0.05). The median capillary blood glucose (CBG) with CSII was significantly lower than with MDI: 7.7 mmol/l (range 3.8-15.4 mmol/l) vs 9.8 mmol/l (range 2.3-27 mmol/l), respectively, p < 0.001. Glycaemic variability with CSII was significantly reduced compared with MDI: CBG CV 0.37 vs CV 0.53, respectively, p < 0.001. CONCLUSIONS/ INTERPRETATION: CSII therapy in patients with diabetic gastroparesis results in significant improvement in glycaemic control and reductions in glycaemic variability and number of hospital inpatient bed days.
Authors: Liza K Phillips; Adam M Deane; Karen L Jones; Chris K Rayner; Michael Horowitz Journal: Nat Rev Endocrinol Date: 2014-11-25 Impact factor: 43.330
Authors: Ryan Jalleh; Chinmay S Marathe; Christopher K Rayner; Karen L Jones; Michael Horowitz Journal: Curr Diab Rep Date: 2019-12-02 Impact factor: 4.810
Authors: Jorge Calles-Escandón; Kenneth L Koch; William L Hasler; Mark L Van Natta; Pankaj J Pasricha; James Tonascia; Henry P Parkman; Frank Hamilton; William H Herman; Marina Basina; Bruce Buckingham; Karen Earle; Kjersti Kirkeby; Kristen Hairston; Tamis Bright; Amy E Rothberg; Andrew T Kraftson; Elias S Siraj; Angela Subauste; Linda A Lee; Thomas L Abell; Richard W McCallum; Irene Sarosiek; Linda Nguyen; Ronnie Fass; William J Snape; Ivana A Vaughn; Laura A Miriel; Gianrico Farrugia Journal: PLoS One Date: 2018-04-13 Impact factor: 3.240
Authors: Andrea Shin; Michael Camilleri; Irene Busciglio; Duane Burton; Elizabeth Stoner; Patrick Noonan; Keith Gottesdiener; Steven A Smith; Adrian Vella; Alan R Zinsmeister Journal: Diabetes Care Date: 2012-09-06 Impact factor: 19.112